Focus Issue: Aspirin
State-of-the-Art Paper
Aspirin Resistance and Atherothrombotic Disease

https://doi.org/10.1016/j.jacc.2004.08.070Get rights and content
Under an Elsevier user license
open archive

Acute coronary syndromes and other manifestations of atherothrombotic disease are primarily caused by atherosclerotic plaque rupture or fissuring and subsequent occlusive or subocclusive thrombus formation. Platelets play a critical role in the pathophysiology of atherothrombotic disease, and aspirin is the most commonly used antiplatelet agent. Clinical trials have demonstrated the efficacy of aspirin in both primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death. Despite its proven benefit, the absolute risk of recurrent vascular events among patients taking aspirin remains relatively high, an estimated 8% to 18% after two years. Therapeutic resistance to aspirin might explain a portion of this risk. Although formal diagnostic criteria and a validated method of measurement are lacking, aspirin resistance may affect between 5% and 45% of the population. Given the prevalence of cardiovascular disease, the potential impact of aspirin resistance is large. Currently, however, there are many unanswered questions regarding the biological mechanism, diagnosis, population prevalence, clinical relevance, and optimal therapeutic intervention for aspirin resistance.

Abbreviations and Acronyms

ADP
adenosine diphosphate
CAD
coronary artery disease
COX
cyclooxygenase
CRP
C-reactive protein
MI
myocardial infarction
NSAIDs
non-steroidal anti-inflammatory drugs
PFA
platelet function analyzer
PG
prostaglandin
PGH2
prostaglandin H2
PGI2
endothelium-derived prostacyclin
PURSUIT
Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy trial
RPFA
rapid platelet function assay
TX
thromboxane

Cited by (0)